Bariatric Surgery vs. Lifestyle Modification for NASH
BeLEANeR
1 other identifier
interventional
50
1 country
1
Brief Summary
Randomized Controlled Trial comparing the effects of Bariatric Surgery vs. Lifestyle modification on NASH resolution.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Feb 2020
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 19, 2020
CompletedFirst Submitted
Initial submission to the registry
March 4, 2020
CompletedFirst Posted
Study publicly available on registry
March 6, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 20, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
March 20, 2022
CompletedMarch 6, 2020
March 1, 2020
2.1 years
March 4, 2020
March 4, 2020
Conditions
Outcome Measures
Primary Outcomes (1)
NASH resolution
NASH resolution evaluated by liver biopsy
12 months
Study Arms (2)
Bariatric Surgery
EXPERIMENTALObese patients, BMI from 30 to 45, with or without type 2 diabetes, submitted to either laparoscopic Roux-en-Y Gastric Bypass or laparoscopic Sleeve Gastrectomy
Lifestyle Modification
ACTIVE COMPARATORObese patients, BMI from 30 to 45, with or without type 2 diabetes, submitted to guided diet and physical activity.
Interventions
laparoscopic Roux-en-Y gastric bypass or laparoscopic Sleeve Gastrectomy
guided low-calorie diet and physical activity.
Eligibility Criteria
You may qualify if:
- BMI between 30 and 45
- with biopsy-proven NASH
- with or without type 2 diabetes
- that fit for bariatric surgery.
You may not qualify if:
- borderline NASH ou cirrhosis;
- alcohol consumption (\> 20 g/day for men and \> 10 g/day for women, for the last 2 years);
- other hepatic diseases (such as viral hepatitis, autoimmune hepatitis, drug-induced hepatic disease, Wilson's disease, hemochromatosis);
- HIV infection;
- unable to provide informed consent;
- previous foregut or bariatric surgery;
- malignancy;
- patients that unfit for bariatric surgery.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hospital de Clínicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, 90035-903, Brazil
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Guilherme S Mazzini, MD, PhD
Hospital de Clínicas de Porto Alegre
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Masking Details
- Blinded pathologist
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 4, 2020
First Posted
March 6, 2020
Study Start
February 19, 2020
Primary Completion
March 20, 2022
Study Completion
March 20, 2022
Last Updated
March 6, 2020
Record last verified: 2020-03